ILARIS canakinumab 150 mg powder for injection

Land: Australien

Sprache: Englisch

Quelle: Department of Health (Therapeutic Goods Administration)

Wirkstoff:

Canakinumab, Quantity: 150 mg

Verfügbar ab:

Novartis Pharmaceuticals Australia Pty Ltd

INN (Internationale Bezeichnung):

Canakinumab

Darreichungsform:

Injection, powder for

Zusammensetzung:

Excipient Ingredients: sucrose; histidine; histidine hydrochloride monohydrate; polysorbate 80; dilute hydrochloric acid

Verabreichungsweg:

Subcutaneous

Einheiten im Paket:

1, 4

Verschreibungstyp:

(S4) Prescription Only Medicine

Anwendungsgebiete:

Ilaris is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children aged 2 years or older including: Familial Cold Autoinflammatory Syndrome (FCAS) /Familial Cold Urticaria (FCU); Muckle-Wells Syndrome (MWS); Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA). Ilaris is indicated for the treatment of active Systemic Juvenile Idiopathic Arthritis (sJIA) in patients aged 2 years or older.

Produktbesonderheiten:

Visual Identification: White solid lyophilisate; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store at 2 to 8 degrees Celsius

Berechtigungsstatus:

Registered

Berechtigungsdatum:

2010-05-10